|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Sunesis Pharmaceuticals, Inc. (SNSS) Release: Vosaroxin Review Published in Expert Opinion on Investigational Drugs
7/24/2012 9:25:21 AM
SOUTH SAN FRANCISCO, Calif., July 24, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of a peer-reviewed paper in the August 2012 issue of Expert Opinion on Investigational Drugs (Volume 21, Number 8) featuring vosaroxin, the Company's lead product candidate currently being evaluated in a Phase 3 trial, the VALOR trial, for the treatment of relapsed or refractory acute myeloid leukemia (AML). The paper, titled "Vosaroxin: a novel antineoplastic quinolone," was written by Jonathan Abbas, MD, and Robert Stuart, MD, of the Medical University of South Carolina, Hollings Cancer Center. The paper provides an in-depth review of the development history of vosaroxin, its mechanism of action, pharmacology, metabolism, as well as preclinical and clinical data to date, and is available online at http://informahealthcare.com/doi/pdf/10.1517/13543784.2012.699038.
|
|
|
|
|
|
|
|
|
|
|